Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease - The DIVINE study

► Ibandronate quarterly 3 mg IV injection is well tolerated in women with PMO and at risk for renal disease. ► IV ibandronate can be used even in patients with pre-existing hypertension or diabetes mellitus. ► Ibandronate injection can be administered safely in the primary care setting. ► IV ibandronate showed comparable safety to oral alendronate in women with postmenopausal osteoporosis (PMO) at increased risk for renal disease.